Veterinary Financing – Joli Jaunter http://jolijaunter.com/ Mon, 12 Jul 2021 13:08:50 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://jolijaunter.com/wp-content/uploads/2021/06/icon-1-150x150.png Veterinary Financing – Joli Jaunter http://jolijaunter.com/ 32 32 LexaGene’s MiQLab provides rapid plague detection for https://jolijaunter.com/lexagenes-miqlab-provides-rapid-plague-detection-for/ https://jolijaunter.com/lexagenes-miqlab-provides-rapid-plague-detection-for/#respond Thu, 17 Jun 2021 11:45:00 +0000 https://jolijaunter.com/lexagenes-miqlab-provides-rapid-plague-detection-for/ BEVERLY, Mass., June 17, 2021 (GLOBE NEWSWIRE) – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, is pleased to announce that today the Dr. Jack Regan, CEO and Founder of LexaGene, will present at the Threat and Pathogen Detection conference the ability of the MiQLab ™ system to detect the pathogen responsible […]]]>

BEVERLY, Mass., June 17, 2021 (GLOBE NEWSWIRE) – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, is pleased to announce that today the Dr. Jack Regan, CEO and Founder of LexaGene, will present at the Threat and Pathogen Detection conference the ability of the MiQLab ™ system to detect the pathogen responsible for plague.

Dr Jack Regan says: “Our MiQLab system is both open access and designed for point-of-care use, making it a Ffirstofhiskind system. These unique characteristics are essential for early point-of-care diagnostics, improving the likelihood of successful biocontainment of new pathogens. The past 18 months have highlighted how much humanity needs advanced technologies like MiQLab to better contain a new pathogen capable of causing a pandemic. MiQLab is uniquely suited to fill the massive technology gap in our testing infrastructure as it has the potential to dramatically reduce the response time from the initial identification of a new pathogen to the rapid deployment of new detection tests at the point of care. . Minimizing this response time dramatically improves the chances of successful containment of pathogens so that countless lives can be saved. “

A brief interview with Dr. Regan regarding LexaGene’s value proposition for pandemic prevention can be viewed HERE.

The 28e International Biothreat and Pathogen Detection Conference is an internationally recognized meeting for experts in the detection and identification of biological threats. This conference addresses key topics in pathogen detection and presents the latest technological and R&D innovations in rapid pathogen identification. In addition, this meeting focuses on the latest strategies to overcome obstacles surrounding the rapid identification of global biological threats and the introduction of new laboratory technologies in the field.

History is replete with numerous cases of natural epidemics of biological threat agents that have collectively killed hundreds of millions of people. Plague is arguably the deadliest pathogen of all time. Other pathogens also caused massive loss of life, including the 1918 influenza pandemic, HIV, Ebola,1 and SARS-CoV-2. Unfortunately, the intentional use of biomenace agents has been documented from the Middle Ages until the two world wars and even into modern times.2 Most recent examples include the 1984 Salmonella bioterrorist attack in Oregon3 and the 2001 anthrax letters.4

The plague has caused many pandemics in human history.5 Due to its history as a killer and the possibility that the plague will still cause a large number of deaths and the difficulty of successful containment, it is classified by the government as a Category A bioterrorism agent.6

In order to demonstrate the capabilities of MiQLab for the detection of biomenace agents, LexaGene developed a plague test and performed an analytical evaluation with artificial samples.

Dr Regan comments: “I am extremely satisfied with the quality of our plague test. In silico analysis showed close to 100% coverage of all plague genomes. Analytical studies have shown that our test correlated extremely closely with quantitative culture (R2 > 0.94). Our test is also very sensitive, as we were able to reliably detect levels 1000 times lower than the levels of this bacterium commonly detected in the blood of infected patients.7 Finally, in an exclusive study, our test was not cross-reacted with any of the phylogenetically related microorganisms tested. These high-quality test results demonstrate MiQLab’s capabilities as a monitoring and detection tool in the face of a natural or intentional biological threat.

To learn more about LexaGene and the MiQLab system or to subscribe to company updates, visit www.lexagene.com or follow us on Twitter or LinkedIn.

On behalf of the board of directors
Dr Jack Regan
Managing Director & Chairman

About LexaGene Holdings Inc.
LexaGene is a molecular diagnostic company that develops molecular diagnostic systems for the detection of pathogens and genetic testing for other molecular markers for rapid on-site testing in veterinary diagnostics, food safety and for use on open access markets such as clinical research, agricultural testing and biodefense. End users simply need to take a sample, load it onto the instrument with a sample preparation cartridge, enter the sample ID and press “Go”. The MiQLab ™ System offers excellent sensitivity, specificity and detection range and can return results in approximately two hours. The unique open access feature is designed for custom testing so end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including availability of funds, results of fundraising efforts, success of technology development efforts, cost of purchasing critical parts, instrument performance, market acceptance of the technology , regulatory acceptance and licensing issues – which could cause actual results to differ materially from the Company’s expectations, as disclosed in Company documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

[1] Walper SA, et al. Detection of biomenace agents: from current diagnostics to the development of sensor technologies. ACS Sens. 2018; 3: 1894-2024.

[2] Riedel, S. Biological warfare and bioterrorism: a historical review. BUMC Proc. 2004, 17, 400-406.

[3] https://www.foodsafetynews.com/2009/10/for-the-first-12/

[4] https://www.npr.org/2011/02/15/93170200/timeline-how-the-anthrax-terror-unfolded

[5] https://en.wikipedia.org/wiki/Pandemic

[6] https://emergency.cdc.gov/agent/agentlist-category.asp

[7] Montminy, S., Khan, N., McGrath, S. et al. Yersinia pestis virulence factors are overcome by a strong lipopolysaccharide response. Nat Immunol 7, 1066-1073 (2006). https://doi.org/10.1038/ni1386

        
]]>
https://jolijaunter.com/lexagenes-miqlab-provides-rapid-plague-detection-for/feed/ 0
Synchrony Financial – Consensus indicates upside potential of 9.5% https://jolijaunter.com/synchrony-financial-consensus-indicates-upside-potential-of-9-5/ https://jolijaunter.com/synchrony-financial-consensus-indicates-upside-potential-of-9-5/#respond Wed, 16 Jun 2021 08:29:28 +0000 https://jolijaunter.com/synchrony-financial-consensus-indicates-upside-potential-of-9-5/ Synchrony Financial with ticker code (SYF) now have 19 analysts covering the stock. Analyst consensus indicates a “Buy” rating. The range between the high target price and the low target price is between 41 and 26 by calculating the average target price that we see 32.42. Given that the previous close of shares was at […]]]>

Synchrony Financial with ticker code (SYF) now have 19 analysts covering the stock. Analyst consensus indicates a “Buy” rating. The range between the high target price and the low target price is between 41 and 26 by calculating the average target price that we see 32.42. Given that the previous close of shares was at 29.61, this indicates that there is a potential upside of 9.5%. The 50-day moving average is now at 27.32 and the 200-day moving average is 23.92. The company has a market capitalization of $ 17,163 million. You can visit the company’s website by visiting: http://www.synchrony.com

Synchrony Financial is a consumer financial services company in the United States. It offers a range of specialized financing programs and banking products to consumers in the digital, retail, home, automotive, travel, health and pet industries. The company also offers private label credit cards, dual cards, general purpose co-branded credit cards, and small and medium business credit products; and promotional financing for consumer purchases, such as private label credit cards and installment loans. In addition, it provides promotional financing to consumers for health procedures, veterinary and personal care, as well as services and products, such as dental care, vision, audiology and cosmetics; debt cancellation products; and deposit products, including certificates of deposit, individual retirement accounts, money market accounts and savings accounts for retail and commercial clients, as well as deposits through brokerage firms in third-party securities. The company offers its credit products through established programs with a group of national and regional retailers, local traders, manufacturers, purchasing groups, industry associations and health service providers; and deposit products through various channels, such as digital and print. Synchrony Financial was incorporated in 2003 and is headquartered in Stamford, Connecticut.

You can now share this on Stocktwits, just click on the logo below and add the ticker in the text to be seen.

]]>
https://jolijaunter.com/synchrony-financial-consensus-indicates-upside-potential-of-9-5/feed/ 0
Brains Bioceutical Corp. and major investor DSM Ventureing closed US $ 31.9 million financing https://jolijaunter.com/brains-bioceutical-corp-and-major-investor-dsm-ventureing-closed-us-31-9-million-financing/ https://jolijaunter.com/brains-bioceutical-corp-and-major-investor-dsm-ventureing-closed-us-31-9-million-financing/#respond Wed, 16 Jun 2021 06:00:00 +0000 https://jolijaunter.com/brains-bioceutical-corp-and-major-investor-dsm-ventureing-closed-us-31-9-million-financing/ Brains Bioceutical Corp. (“Brains” or “Company”) is pleased to announce the completion of a US $ 31.9 million financing with existing shareholders of DSM Ventureing and Brains. As the primary investor in this cycle, DSM Venture Capital is the corporate venture capital arm of Royal DSM (“DSM”). DSM is a global science-based company active in […]]]>

Brains Bioceutical Corp. (“Brains” or “Company”) is pleased to announce the completion of a US $ 31.9 million financing with existing shareholders of DSM Ventureing and Brains. As the primary investor in this cycle, DSM Venture Capital is the corporate venture capital arm of Royal DSM (“DSM”). DSM is a global science-based company active in the fields of health and nutrition. And a sustainable way of life. This historic investment and strategic transaction strengthens Brains’ position as one of the leading cannabinoid (CBD) pharmaceutical companies. Del Morgan & Co. acted as Brains’ financing agent.

“Completion of the financing marks an exciting milestone for the Brains team. Gaining DSM’s confidence in the next round strengthens Brains’ strategic position in the pharmaceutical industry, ”said Rick Brar, CEO and President of Brains. “The demand for isolated CBD active pharmaceutical ingredients (APIs) in the pharmaceutical and healthcare industry continues to grow. Our team has worked tirelessly to position Brains as the market leader in the CBD industry. Our license suite allows Brains to grow rapidly within the industry, ”continued Blair.

Pieter Wolters, Managing Director of DSM Ventureing, commented: “The CBD market is growing rapidly and increasingly strong scientific evidence proves the potential of API CBD in many therapeutic areas. Additionally, consumers are increasingly turning to CBD to solve their health concerns. . Brains’ unrivaled expertise and manufacturing capabilities in the area of ​​CBD, coupled with Godsman’s unique scientific and marketing capabilities in the pharmaceutical arena, make it an ideal partnership to help pharmaceutical companies realize the potential of early drug development. of CBD.

Brains is one of the few companies in the world to produce CBD as an API for pharmaceutical applications, research, development and clinical trials. It is also one of the few commercial manufacturers in Europe to achieve EU-GMDP certification, producing CBD APIs for human and veterinary use in facilities approved by the MHRA. Brains’ API CBD, its leading product on the market, contains 99.7% CBD and zero tetrahydrocannabinol (THC).

Brains’ progress in the development of pure natural CBD benefits scientific and health communities around the world. Brains Phytocannabinoid Pure CBD API has successfully passed the INRS laboratory test of the World Anti-Doping Agency (WADA). These screening reports confirm that Brains API CBD does not contain tetrahydrocannabinol, pesticides and other banned substances listed by WADA. Brains is the first in the industry to obtain such confirmation of the purity of its CBD and the absence of banned substances from a laboratory accredited by WADA. WADA has removed CBD from its list of banned substances. All activities carried out in the UK comply with UK law and are subject to routine and regular inspections by UK authorities.

Brains has also launched its ‘Brains Pure’ branded CBD nutritional supplement in major UK health and wellness retail and pharmacy chains. All Brains products, whether under the Brains brand or the white label, including a collaboration with a leading UK vitamin company, will carry the ‘Brains Inside®’ brand and provide a seal of assurance. quality. Brains is also able to meet the stringent new dietary requirements of the British Food Standards Association (FSA) and the European Food Safety Authority (EFSA) for CBD products in the UK. Brains’ collaboration with DSM Ventureing will allow the company to leverage the strategic partnership that DSM has established since its initial inception in 1902.

About Brain Biopharmaceutical Company.

Brains Bioceutical Corp. is a leader in the production of natural active pharmaceutical ingredients (APIs) in the pharmaceutical and nutraceutical industry which is GMP certified by the European Union. Brains Bioceutical is one of the only manufacturers of natural phytocannabinoid active pharmaceutical ingredients (APIs) currently in commercial production and has participated in global academic and clinical trials. The Brains leadership team is made up of a few pharmaceutical and consumer product executives. They have held managerial and other leadership positions in companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and the Royal Navy. Brains is owned by a wholly British subsidiary. BSPG Laboratories is one of the few companies with commercial capabilities and EU-GMDP certification to produce CBD APIs.

About DSM Entrepreneurship

DSM Ventureing is the corporate venture capital arm of Royal DSM. Royal DSM is a goal-oriented global science company active in nutrition, health and sustainable lifestyles. DSM’s mission is to create a better life for everyone. DSM uses its products and solutions to address some of the world’s greatest challenges, while creating economic, environmental and social value for all stakeholders: customers, employees, shareholders and society as a whole. DSM provides innovative solutions for human nutrition, animal nutrition, personal care and flavors, medical equipment, green products and applications, as well as new mobility and connectivity. DSM and its subsidiaries have approximately 23,000 employees and annual net sales of approximately € 10 billion. The company was founded in 1902 and listed on Euronext Amsterdam.

More information can be found at www.dsm.com/venturing.

Warning :

This press release contains forward-looking statements or forward-looking information within the meaning of securities laws (“forward-looking statements”). Usually, but not always, forward-looking statements may be made by means of “plans”, “expect” or “unexpected”, “anticipates”, “estimates”, “intentions”, “expects” or “unexpected beliefs” , or variations of such words and expressions, or state that certain actions, events or results “may”, “may”, “shall”, “may” or “shall” occur or be achieved. All statements contained in this press release other than statements of historical fact are forward-looking statements and are based on expectations, estimates and forecasts as of the date of this press release. All statements that involve discussions of predictions, expectations, beliefs, plans, forecasts, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. The risks, uncertainties and other factors involved in forward-looking statements may cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied in such forward-looking statements. Although the company believes that the assumptions and factors used in preparing the forward-looking statements in this press release are reasonable, it cannot guarantee that such statements will prove to be accurate as actual results and future events may differ materially from expectations. In the statement. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The forward-looking statements contained in this press release were made as of the date of this press release. Unless otherwise applicable securities requirements, the Company assumes no obligation to publicly update these forward-looking statements to reflect new information, subsequent events or other circumstances. .

]]>
https://jolijaunter.com/brains-bioceutical-corp-and-major-investor-dsm-ventureing-closed-us-31-9-million-financing/feed/ 0
Govt. seeks to increase the number of govt. schoolchildren in professional classes https://jolijaunter.com/govt-seeks-to-increase-the-number-of-govt-schoolchildren-in-professional-classes/ https://jolijaunter.com/govt-seeks-to-increase-the-number-of-govt-schoolchildren-in-professional-classes/#respond Tue, 15 Jun 2021 20:59:26 +0000 https://jolijaunter.com/govt-seeks-to-increase-the-number-of-govt-schoolchildren-in-professional-classes/ The government of Tamil Nadu led by Chief Minister MK Stalin on Tuesday appointed an 11-member commission to recommend measures to increase the representation of students from the state’s public schools in professional courses (other than medicine), if their admission to such programs is not adequate. The commission, which will be headed by the retired […]]]>

The government of Tamil Nadu led by Chief Minister MK Stalin on Tuesday appointed an 11-member commission to recommend measures to increase the representation of students from the state’s public schools in professional courses (other than medicine), if their admission to such programs is not adequate.

The commission, which will be headed by the retired Delhi High Court Judge Judge D. Murugesan, will examine the socio-economic conditions of public school students, the disadvantages they experience, if any, and their past enrollment in various vocational courses / educational institutions. . He will submit his report to the government in a month.

“If the above issues have led to their under-representation, [the panel will] suggest corrective measures to improve the representation of students of state public schools in admission to professional courses such as engineering / agriculture / veterinary medicine / fisheries / law, etc.

The panel will assess and analyze the reasons why fewer public school students are admitted to these professional courses at reputable public and self-funded universities and colleges.

Besides Mr. Murugesan, Secretaries of Higher Education, Livestock, Dairy, Fisheries and Fishermen’s Welfare, Health Education and Family Welfare, Education School, Agriculture and Farmers Welfare Department and Legal Departments, Registrar of Anna University and Secretary of Tamil Nadu Engineering Admission are the other members. The Directorate of Technical Education will be its member secretary.

The government’s move follows representations from various sections, which said the number of public school students in such vocational courses at reputedly self-funded universities and public colleges has been low in recent years. They further requested that their representation in these courts in these institutions be improved.

The government earlier this month formed a high-level committee to study the impact of NEETs on medical admissions. If this is the case, the panel has been tasked with proposing “fair and equitable methods”.

The former AIADMK government had enacted a law to provide a 7.5% reservation to public school students in medical admissions in Tamil Nadu based on their NEET scores.

]]>
https://jolijaunter.com/govt-seeks-to-increase-the-number-of-govt-schoolchildren-in-professional-classes/feed/ 0
Finance in Motion facilitates € 760m of new sustainability investments in emerging markets in 2020 (new with additional features) https://jolijaunter.com/finance-in-motion-facilitates-e-760m-of-new-sustainability-investments-in-emerging-markets-in-2020-new-with-additional-features/ https://jolijaunter.com/finance-in-motion-facilitates-e-760m-of-new-sustainability-investments-in-emerging-markets-in-2020-new-with-additional-features/#respond Mon, 14 Jun 2021 10:21:34 +0000 https://jolijaunter.com/finance-in-motion-facilitates-e-760m-of-new-sustainability-investments-in-emerging-markets-in-2020-new-with-additional-features/ Finance in Motion facilitates € 760m of new sustainability investments in emerging markets in 2020 (new with additional features)Frankfurt, June 14, 2021 – Finance in Motion, one of the world’s leading impact asset managers, released its annual impact investing report. Entitled “Investing in resilience“, the publication details how, thanks to the funds it advises and manages, the company directed 760 million euros of new investments towards sustainable development in 2020 – the highest […]]]> Finance in Motion facilitates € 760m of new sustainability investments in emerging markets in 2020 (new with additional features)

Frankfurt, June 14, 2021 – Finance in Motion, one of the world’s leading impact asset managers, released its annual impact investing report. Entitled “Investing in resilience“, the publication details how, thanks to the funds it advises and manages, the company directed 760 million euros of new investments towards sustainable development in 2020 – the highest ever recorded in a year for the asset manager More than 400 technical assistance interventions supported these financial activities to strengthen their impact and help companies meet operational challenges, particularly in response to the coronavirus crisis.

Finance in Motion advises or manages various impact funds dedicated exclusively to sustainable development in emerging markets. The funds channel investments into topics such as climate action, biodiversity conservation, sustainable use of natural resources, entrepreneurship and financial inclusion. Particularly given the global disruption caused by the pandemic, funds in 2020 have focused on sustaining or accelerating essential funding and technical assistance in these areas. For example, funding for local businesses helped support 114,000 jobs, while investments in green energy and energy efficiency measures in 2020 helped reduce CO emissions.2 emissions at a rate of 971,000 tonnes per year.

“Investing in Resilience” describes in detail Finance in Motion’s approach to these activities, through detailed information on the company’s impact and sustainability strategy – including measurement and impact monitoring, and alignment with the United Nations Sustainable Development Goals – as well as case studies and key figures.

“Impact investing has always been about problem solving,” said Managing Director Sylvia Wisniwski. “Managing the crisis is nothing new for us. It is in fact a constant and essential characteristic of our business. When Finance in Motion was established in 2009, many issuers were struggling with the financial crisis. Today is the pandemic with all its global ramifications.But then as now, maintain long-term business relationships with our partners who work not only on sunny days but also on stormy days, to maintain a Field presence in our markets and having a deep understanding of our partners have all helped build resilient systems capable of overcoming shocks, delivering targeted interventions, and continuing to drive sustainable development. We hope, with this report, to offer examples of how collaboration and innovation are essential to tackle even daunting challenges – and how impact investing can help come out even stronger than before. ”

Click here to read “Investing in resilience”, the impact report of Finance in Motion 2020.

About Finance on the Move

Finance in Motion is a global impact asset manager focused exclusively on sustainability in emerging markets. The company develops and advises impact investment funds whose blended finance structures bring together public and private investors to fight climate change, strengthen the conversation on biodiversity, promote the sustainable use of natural resources, improve livelihoods and promote economic opportunities.

Over the course of its operations, Finance in Motion has released a cumulative total of over 5.4 billion euros towards these goals in South East Europe, the Caucasus, Latin America, the Middle East, and South Africa. North and sub-Saharan Africa. In addition to investment activities, the funds also provide technical assistance to support recipient businesses, foster responsible finance and maximize impact in the countries they serve. Finance in Motion also makes selected direct investments in high impact companies that share the company’s values.

With 17 offices operating in more than 30 countries, Finance in Motion helps partners grow their businesses and demonstrate that financial and sustainable returns can go hand in hand.

For more information, please visit us at: www.finance-in-motion.com
You can also follow us on Twitter @financeinmotion and on LinkedIn

Finance in Motion media contact

Merle Römer
Manager, Marketing and Communications
Telephone: +49 69/271 035-171
Fax: +49 69/271 035-110
Email: m.roemer@finance-in-motion.com

]]>
https://jolijaunter.com/finance-in-motion-facilitates-e-760m-of-new-sustainability-investments-in-emerging-markets-in-2020-new-with-additional-features/feed/ 0
Africa Energy Week 2021, which takes place in Cape Town; Will focus on investment, oil and gas, renewable energies and energy transition https://jolijaunter.com/africa-energy-week-2021-which-takes-place-in-cape-town-will-focus-on-investment-oil-and-gas-renewable-energies-and-energy-transition/ https://jolijaunter.com/africa-energy-week-2021-which-takes-place-in-cape-town-will-focus-on-investment-oil-and-gas-renewable-energies-and-energy-transition/#respond Mon, 14 Jun 2021 10:15:04 +0000 https://jolijaunter.com/africa-energy-week-2021-which-takes-place-in-cape-town-will-focus-on-investment-oil-and-gas-renewable-energies-and-energy-transition/ Africa Energy Week 2021, which takes place in Cape Town;  Will focus on investment, oil and gas, renewable energies and energy transitionDGAP-News: African Chamber of Energy / Keyword (s): Miscellaneous 14.06.2021 / 12:15 The issuer is solely responsible for the content of this advertisement. Africa Energy Week 2021, which takes place in Cape Town; Will focus on investment, oil and gas, renewable energies and energy transition – The African Energy Chamber (https://EnergyChamber.org) is expected to host […]]]> Africa Energy Week 2021, which takes place in Cape Town;  Will focus on investment, oil and gas, renewable energies and energy transition

DGAP-News: African Chamber of Energy / Keyword (s): Miscellaneous
14.06.2021 / 12:15
The issuer is solely responsible for the content of this advertisement.

Africa Energy Week 2021, which takes place in Cape Town; Will focus on investment, oil and gas, renewable energies and energy transition

The African Energy Chamber (https://EnergyChamber.org) is expected to host the very first African Energy Week (AEW) in Cape Town from November 9-12, 2021.

Replacing Africa Oil Week, the four-day interactive conference aims to unite industry stakeholders, international speakers and stakeholders in the African oil and gas sector.

The conference features high-class networking events, innovative exhibits and private one-on-one meetings, with a golf tournament on the last day, providing a unique experience for stakeholders interested in the growth and success of the energy sector in Africa.

Download Image: https://bit.ly/35j3llO

Johannesburg, June 14, 2021 – The African Energy Chamber (AEC) is delighted to announce the official launch of African Energy Week (AEW) 2021, which will take place in Cape Town on November 9 – 12, 2021. AEW 2021 will feature the first-ever African Energy Village, an interactive exhibition and networking event that aims to unite African energy players, spur industry growth and development, and promote Africa as the destination for events focused on Africa.

Starting with a three-day conference and ending with a golf tournament on November 12, the main objective of the event is to define and promote the African energy agenda through development, agreement-making and private sector involvement. Key topics include ending energy poverty by 2030 and the future of Africa’s oil and gas industry; African opportunities upstream, mid-term and downstream; African oil, gas and finance facing the energy transition – highlighting African financing institutions such as the African Development Bank, the African Import-Export Bank, the African Finance Corporation, Africa50, the Industrial Development Corporation and the Development Bank of Central African States; local content; women in energy and make African energy competitive for investment in a carbon-free Africa.

In addition, the conference will address the role of the Organization of the Petroleum Exporting Countries (OPEC), the Gas Exporting Countries Forum (GECF), the International Energy Agency (IEC), the African Organization from Petroleum Producers (APPO), the International Association of Geophysical Contractors (IAGC), and the American Petroleum Institute (API) and Africa. By opening the dialogue on Africa’s gas miracle and its potential in markets such as Senegal, Mozambique, Nigeria, Ghana, South Africa, Algeria, Tanzania, Equatorial Guinea, Congo-Brazzaville and Angola – along with small-scale liquefied natural gas, intra-African trade and the African Continental Free Trade Agreement – the conference represents the ideal networking and negotiating platform for all African energy players.

The ACS commitment to host this Africa-focused event in Africa comes at a critical time for the oil and gas industry. In light of recent developments which seek to suggest that Africa is not capable of hosting world-class events, the Chamber feels responsible to speak out against this and lead by example by showcasing the continent and all its deep beauty.

With that in mind, the only Africa-focused in-person energy event aims to capture the essence and cultural hub that exists in Cape Town. The AEC will not abandon the continent for international competitions. AEW 2021 is an energy event like no other and the ACS is fully focused on promoting Africa’s development and growth through events held in Africa.

“We are happy with the tremendous support from so many African and foreign countries. Our oil and gas producers have been a force for good and we should be proud of this industry. We must also embrace the energy transition and engage Africa with the most energetic conversation and solutions for the future. AEW 2021 offers a unique and interactive networking experience in which global energy players can unite and participate in the transformation of the continent. The time has come, ”said NJ Ayuk, Executive Chairman of the African Energy Chamber.

“Africa Energy Week will have a bold message that encourages energy solutions that reduce rights, handouts and foreign aid. No one owes us anything and for so many Africans who want to make energy poverty triumph, we must embrace all of them. forms of energy in our energy mix We need to attract investors and strengthen our leadership so that every country wins when we create and foster an enabling environment, ”adds Ayuk.

AEW 2021 is taking place with the full support of prominent African and global industry leaders and oil and gas organizations and focuses on expanding opportunities in Africa. Additionally, AEW 2021 will feature innovative exhibition spaces at Cape Town’s V&A Waterfront that aim to promote African heritage and culture, while showcasing the exciting technological advancements the industry has to offer.

“African energy producers can only grow and meet the demand for energy when we all do our best to mobilize our resources and defend important principles of personal responsibility, smaller government, lower taxes, free markets, personal freedom and the rule of law. start the investment and make a transition that works for Africa. Let’s do it in Africa, for Africa and for the energy sector, ”Ayuk concludes.

Equally important, the event will take place under strict COVID-19 protocols to ensure the safety of all attendees. In accordance with applicable government regulations, AEW 2021 will host a series of networking events at various locations across the V&A Waterfront, ensuring that social gathering limits are in place at all times. Additionally, through mandatory testing and the availability of personal protective equipment and facilities, AEW 2021 aims to protect attendees while ensuring a successful and productive event.

Distributed by APO Group on behalf of the African Energy Chamber.

For more information on this transformative event, visit www.aew2021.com or www.energychamber.org and / or email Amina Williams at amina.williams@energychamber.org

For any request relating to registration, contact inscription@aew2021.com
For sales inquiries, contact sales@aew2021.com
For media inquiries, contact media@aew2021.com
For inquiries related to speaker opportunities, contact orateurs@aew2021.com

06.14.2021 Distribution of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on www.dgap.de

]]>
https://jolijaunter.com/africa-energy-week-2021-which-takes-place-in-cape-town-will-focus-on-investment-oil-and-gas-renewable-energies-and-energy-transition/feed/ 0
Maine Senate supports Miramant bill to increase funding for schools https://jolijaunter.com/maine-senate-supports-miramant-bill-to-increase-funding-for-schools/ https://jolijaunter.com/maine-senate-supports-miramant-bill-to-increase-funding-for-schools/#respond Mon, 14 Jun 2021 05:44:41 +0000 https://jolijaunter.com/maine-senate-supports-miramant-bill-to-increase-funding-for-schools/ The Senate passed a bill from Senator David Miramant, D-Camden, on Monday, June 7, which would force the state of Maine to meet its 55% school contribution requirement. Law LD 1114, “An Act to Require the State to Respect the Mandatory 55% School Contribution,” received unanimous and bipartisan support. LD 1114 would increase the share […]]]>

The Senate passed a bill from Senator David Miramant, D-Camden, on Monday, June 7, which would force the state of Maine to meet its 55% school contribution requirement. Law LD 1114, “An Act to Require the State to Respect the Mandatory 55% School Contribution,” received unanimous and bipartisan support.

LD 1114 would increase the share of state funding for essential services and programs and public schools to 55%. In 2003, voters in Maine passed a citizens’ referendum that required the state to pay 55% of the operating costs of public schools in order to reduce property taxes. Under a supplementary budget proposal from Governor Janet Mills presented in May, the state’s contribution to K-12 public education would meet the 55% threshold in state law for first time in many years.

the Maine School Principals Association; Municipal Association of Maine; Association of School Boards of Maine; The Maine School Superintendents Association and the Maine Education Association have all testified in favor of this bill.

LD 1114 faces further votes in the Legislature.


]]>
https://jolijaunter.com/maine-senate-supports-miramant-bill-to-increase-funding-for-schools/feed/ 0
Is Patient Funding Right For Your Healthcare Practice? https://jolijaunter.com/is-patient-funding-right-for-your-healthcare-practice/ https://jolijaunter.com/is-patient-funding-right-for-your-healthcare-practice/#respond Fri, 11 Jun 2021 19:30:00 +0000 https://jolijaunter.com/is-patient-funding-right-for-your-healthcare-practice/ The advantages and challenges of partnering with an external finance company to facilitate patient care. Free preview of the book Smart Solopreneur This book gives you the essential guide to easy-to-follow tips and strategies to create more financial success. June 11, 2021 4 minutes to read Opinions expressed by Contractor the contributors are theirs. In […]]]>

The advantages and challenges of partnering with an external finance company to facilitate patient care.

Free preview of the book
Smart Solopreneur

This book gives you the essential guide to easy-to-follow tips and strategies to create more financial success.

June 11, 2021

4 minutes to read

Opinions expressed by Contractor the contributors are theirs.


In these times of post-pandemic financial uncertainty, additional return on investment for medical providers is more welcome than ever. Patient financing – which, for the purposes of this article, means partnering with an external lender to provide services and procedural payments – can not only produce stable income for a practice, but help ensure that patients do not ‘will not have to postpone the proceedings or, even worse. , abandon them completely. For example, Toronto Plastic Surgeons offers this facility to its patients through Medicard patient funding. There are also veterinary pet financing services available through Medicard Patient Financing. What are the reasons that practitioners may have used to decide on this option?

No more delays

Unfortunately, there are economic disparities in access to health services. Too often, high incomes and the privileged have more access to health resources than middle and low income populations. Funding for patients can help reduce this imbalance, as the simple and disheartening truth is that many medical issues go unreported and it is often impossible to plan for the associated expenses. With funding, patients don’t have to wait until their accounts are in order before opting for procedures – the result is, ideally, quick and less stressful treatment.

Related: Fintech Fuels Growth in Healthcare Financial Sector

Increased patient satisfaction

Since customers can often manage their expenses better through patient financing, they tend to be more satisfied overall. Part of the reason is that they are not stressed out and burdened with sudden financial decisions associated with urgent medical procedures. Best of all, they’re more likely to stick with a practice if they don’t have to worry so much. Compared to other practices that don’t offer this option, they are more likely to go the former, which can mean more business through word of mouth.

Reduced collection costs

When you partner with a patient funder, you receive payments on time. It also means your team won’t spend unnecessary hours and energy trying to collect payments.

Stable cash flow and less bad debt

By setting up a conventional payment plan for a patient, your team takes responsibility for keeping an eye on payments and collecting them on time. Essentially, it involves giving a loan to a patient, usually without any interest. However, expenses such as bills, payroll, and lease / rent continue as usual. This can lead to money tied up in accounts receivable which will have an easy and quick impact on a budget. But when you choose a partnership with a patient finance company, the latter takes care of the collection costs, including the possibility of being paid up front.

Related: Healthcare Is In Trouble, But Tech Can Save Billions of Businesses

Better marketing

Partnering with a finance company with its own marketing arm can help promote a business, making your clinic stand out from the crowd.

Which one to choose ?

In terms of funding models, three predominate. In the first, self-financing, you, as the care provider, are responsible for the receivables. From creating a payment schedule to fundraising and patient follow-up, your team does it all. In the recourse loan model, you work with a patient financier / lender, who will approve a patient’s loan once the business / practice has met the eligibility criteria. If the patient does not pay, the lender / finance company will recoup the losses from you. Among the disadvantages here is that the practice will have to bear the losses and the costs of the lender. Finally, there is the non-recourse loan model. Similar to the second, you are working with a loan company. The main differences are that it is the patient who must meet the underwriting criteria (if the lender does not approve the patient, no funding is provided by them) and the losses are borne by the lender. A downside to this method is that lenders charge interest to patients; when rates are high, patients may not be interested. Additionally, patients with poor credit histories might be rejected when assessing pricing.

Related: 5 Healthcare Startups To Watch In 2021

]]>
https://jolijaunter.com/is-patient-funding-right-for-your-healthcare-practice/feed/ 0
MigVax Subunit COVID-19 Oral Vaccine Preclinical Trial Demonstrates Efficacy as a Booster https://jolijaunter.com/migvax-subunit-covid-19-oral-vaccine-preclinical-trial-demonstrates-efficacy-as-a-booster/ https://jolijaunter.com/migvax-subunit-covid-19-oral-vaccine-preclinical-trial-demonstrates-efficacy-as-a-booster/#respond Thu, 10 Jun 2021 10:30:11 +0000 https://jolijaunter.com/migvax-subunit-covid-19-oral-vaccine-preclinical-trial-demonstrates-efficacy-as-a-booster/ MigVax Subunit COVID-19 Oral Vaccine Preclinical Trial Demonstrates Efficacy as a BoosterQIRYAT SHMONA, Israel – (COMMERCIAL THREAD) – MigVax Ltd., a start-up developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that have demonstrated the effectiveness of its oral subunit vaccine MigVax-101 as a booster for people previously vaccinated. In the trial, tests in rats demonstrated that the oral subunit vaccine […]]]> MigVax Subunit COVID-19 Oral Vaccine Preclinical Trial Demonstrates Efficacy as a Booster

QIRYAT SHMONA, Israel – (COMMERCIAL THREAD) – MigVax Ltd., a start-up developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that have demonstrated the effectiveness of its oral subunit vaccine MigVax-101 as a booster for people previously vaccinated.

In the trial, tests in rats demonstrated that the oral subunit vaccine MigVax-101, when given as a booster after an injection of S1 protein, caused significantly higher neutralizing antibody titers. than rats given an oral placebo booster. In addition, similar to a third booster injection, it elicited more effective neutralizing antibodies.

MigVax is currently seeking funding to initiate Phase 1 and 2 clinical trials which, if successful, would lead to commercial availability 9 to 12 months after the start of the trials. For full preclinical test results, please refer here.

As an oral vaccine, Mig-Vax-101 offers significant potential advantages over current first generation injected vaccines:

  • Ease of administration: Oral administration avoids the need for administration by healthcare professionals.
  • Uniquely positioned to tackle new variants: The RBD subunit can be quickly adapted to new variants, an advantage that can help guide the production of more efficient neutralizing antibodies. In addition, since the other components of the vaccine consist of a protein which is not subject to change, the vaccine may remain effective longer before it needs a booster.
  • Mucosal immunity: Preclinical data demonstrated marked mucosal IgA in the lung lavage, which means that the oral vaccine offers special protection at the exact point needed: the port of entry of the virus.
  • Ease of transport and storage: Although the MigVax-101 requires refrigeration, it does not require “deep freeze” conditions. This significantly reduces the costs of distribution and storage and logistics.
  • Applicability to a wider population: Since the oral MigVax-101 subunit vaccine does not inject viruses or genetic material into people, it will be much more acceptable to a larger population, including those who are reluctant to receive injections of the material. genetic or viral as well as infants, children, pregnant women, women and certain other segments of the population.

“The results of this trial reinforce our confidence that our subunit oral vaccine MigVax-101 will make a positive contribution to a world facing the new post-pandemic reality,” commented Professor Itamar Shalit, expert in infectious diseases. by MigVax.

“Fifteen months after the start of the pandemic, we now see that the struggle to keep Covid under control is almost as difficult as getting it under control to begin with. Oral boosters such as our MigVax-101 will be key catalysts that will help healthcare organizations around the world move from “panic mode” to routine, due to their ability to reduce costs and expand the reach of health care programs. vaccination in progress. ”

MigVax-101 is a new oral subunit vaccine that uses a chimeric protein to generate three types of simultaneous immunological responses: mucosal, blood and cell-mediated immunity. This three-armed approach offers complete protection against infection by activating all arms of the immune system, allowing the effective eradication of the invading virus. Its epitopes were designed using the computational chemistry of immunogenic epitopes in IBV, MERS, SARS-COV and SAS-COV-2, with a focus on neutralizing antibodies and promoting an immune response.

##

About MigVax:
MigVax Ltd. is developing a new COVID-19 vaccine. MigVax, a subsidiary of Migal Galileo Research Institute. The Migal Galilee Research Institute previously developed a vaccine against the infectious bronchitis virus, a strain of coronavirus that causes bronchial disease affecting poultry. The vaccine’s efficacy against poultry has been proven in animal trials at the Israel Veterinary Institute. MigVax is using methods from the existing vaccine to develop a new human oral subunit vaccine against COVID-19. The first round of investment was led by Our Crowd a global venture capital investment platform that enables institutions and individuals to invest and engage in emerging companies.

For more information, please refer to http://www.migvax.com/ and https://www.migvax.com/copy-of-the-science , or contact:

View the source version on businesswire.com: https://www.businesswire.com/news/home/20210610005425/en/

]]>
https://jolijaunter.com/migvax-subunit-covid-19-oral-vaccine-preclinical-trial-demonstrates-efficacy-as-a-booster/feed/ 0
Movers and shakers 3/6/2021 | Vancouver Business Journal https://jolijaunter.com/movers-and-shakers-3-6-2021-vancouver-business-journal/ https://jolijaunter.com/movers-and-shakers-3-6-2021-vancouver-business-journal/#respond Thu, 03 Jun 2021 22:30:24 +0000 https://jolijaunter.com/movers-and-shakers-3-6-2021-vancouver-business-journal/ LON PLUCKHAHN The City of Vancouver will welcome a new Deputy City Manager to its leadership team this summer. Lon Pluckhahn will assume the role of Deputy City Manager, Community and Economic Development, effective August 2. This deputy position is one of two deputy city manager roles that are part of the city’s new organizational […]]]>

LON PLUCKHAHN

The City of Vancouver will welcome a new Deputy City Manager to its leadership team this summer.

Lon Pluckhahn will assume the role of Deputy City Manager, Community and Economic Development, effective August 2. This deputy position is one of two deputy city manager roles that are part of the city’s new organizational structure to build leadership capacity and better serve the organization’s needs.

In this role, Pluckhahn will oversee community development, parks, recreation and culture, economic development, and policy and program management teams.

Pluckhahn brings more than 25 years of experience in the public sector to Vancouver, including economic development, parks and planning, collective bargaining and capital project financing.

He has served as city manager for the past 14 years in Marion, Iowa – a growing community of 40,000 residents in the state’s second largest subway. Pluckhahn has also served as city manager in Platteville, Wisconsin, and West Liberty, Iowa.

“We are delighted to welcome Lon, his experience and his compassionate leadership style to Vancouver later this summer,” said Eric Holmes, City Manager of Vancouver.

Pluckhahn is an International City Manager’s Association-accredited manager and holds a bachelor’s degree in political science, a master’s degree in public administration, and a master’s degree in community and regional planning, all from Iowa State University.

“I can’t wait to start a new chapter and be a part of the Vancouver community,” Pluckhahn said. “The city has built a solid foundation for well-managed growth and abundant opportunity and I am delighted to be a part of its continued success. “

The city is also currently looking for an Assistant City Manager of Business Services, who will lead human resources, diversity, equity and inclusion, corporate services and information technology. Current Deputy City Manager Brian Carlson has announced he will retire this summer after 20 years with the city.

Jim the King

JIM THE KING

WellHaven Pet Health recently announced that Jim King has been appointed Chief Financial Officer. King was previously senior vice president of finance and has been with WellHaven from the start. He brings a unique blend of accounting, acquisition and operational finance experience to WellHaven and the veterinary profession.

Previously, King worked at PricewaterhouseCoopers (PwC) in their audit and insurance practice before working as Senior Director of Acquisition Integration at Banfield Pet Hospital. His professional background in operational finance, public accounting, and relationship building in individual veterinary clinics has prepared WellHaven Pet Health for continued growth in the years to come. King is also the Treasurer and Board Member of the West Columbia Gorge Humane Society.

CEO Jenni Jones said, “Jim has the unique ability to apply operational thinking and also to consider a corporate culture perspective when making financial decisions. I am excited about his continued leadership within the WellHaven team and am confident in his ability to lead our business development efforts. It will play an important role in our growth strategy.

Chris Perrault

CHRIS PERRAULT

Trelleborg Sealing Solutions, a global leader in engineering polymer solutions that seal, moisten and protect critical applications in demanding environments, recently announced Chris Perrault as Head of ServicePLUS in Vancouver, Wash.

Trelleborg’s ServicePLUS centers support its customers by offering them a full range of engineering activities, streamlining manufacturing processes, ensuring product availability and providing exceptional customer service. In his new role, Perrault will manage a variety of value chain and manufacturing activities for customers in the Portland metro area, freeing them up to free up capital and manpower to focus on things more. important.

Will Bacon, ServicePLUS Segment Manager, said: “Chris has a positive and dynamic attitude, which is extremely important in helping customers optimize product performance, improve their supply chains and maximize throughput. . He also brings with him the warehouse and management skills needed for this role. With Chris on board, we are well positioned to deliver critical, value-added solutions to our customers. “

Perrault has over 23 years of experience managing warehouse operations. Most recently, he served as Director of Operations for the National Performance Warehouse, where he managed more than 50 employees, negotiated with freight suppliers to reduce costs, improve staffing inefficiencies and implement training process.

comments

comments

]]>
https://jolijaunter.com/movers-and-shakers-3-6-2021-vancouver-business-journal/feed/ 0